A Medical Science Liaison (MSL) is a scientific expert who represents a pharmaceutical company in deep, non-commercial dialogue with Key Opinion Leaders (KOLs), physicians, and researchers about new and existing medicines. It is one of the more scientifically demanding roles in pharma, sitting between R&D, medical affairs, and the clinical community.
What an MSL Actually Does
MSLs build long-term relationships with KOLs and medical experts, share clinical data and scientific information in response to unsolicited requests, and support investigator-initiated trials (IITs). They also contribute to medical strategy and advisory boards, and respond to medical-scientific questions from healthcare professionals in the field.
Qualifications for the Role
MSLs typically hold a PhD, PharmD, MD, or another advanced degree in pharmacy, medicine, or biomedical sciences. Strong communication skills and genuine scientific credibility with clinicians are essential, since the role depends entirely on being taken seriously as a peer by physicians and researchers.
MSL Salaries in the Netherlands
MSLs in the Netherlands typically earn between €5,000 and €9,000 gross per month, depending on seniority and therapeutic area. Oncology, rare disease, and cell and gene therapy specializations tend to command the higher end of that range.
Hiring MSLs Through SIRE® Life Sciences
SIRE® Life Sciences maintains a specialized network of MSL professionals with experience in oncology, cardiology, neurology, and rare diseases for pharma and biotech companies across the Netherlands. For related career paths in the same regulatory and clinical ecosystem, see our guides to Regulatory Affairs Careers in Life Sciences and Pharma Careers in the Netherlands.
FAQ
What is the difference between an MSL and a sales representative?
MSLs operate outside the commercial sphere and focus on scientific education, while sales reps pursue commercial objectives.
Can a physician become an MSL?
Yes, physicians are highly valued MSL candidates because of the clinical credibility they bring when engaging with KOLs.
This article is adapted from the original piece on the SIRE Life Sciences blog.
Top comments (0)